Vertex reports Phase 2b kidney disease drug data, enrolls Phase 2/3 trial
Tweet Send to a Friend
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced results from its Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




